Hereditary factors in endometrial cancer by Tzortzatos, Gerasimos
Department of Women’s and Children’s Health, 
Karolinska Institutet, Stockholm, Sweden 
HEREDITARY FACTORS IN ENDOMETRIAL 
CANCER  
GERASIMOS TZORTZATOS, M.D. 
 
 
Stockholm 2015 
 
  
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by E-Print AB 2015 
© Gerasimos Tzortzatos, 2015 
ISBN 978-91-7549-812-6 
 
 
HEREDITARY FACTORS IN ENDOMETRIAL CANCER  
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
GERASIMOS TZORTZATOS, MD 
Principal Supervisor: 
Associate Professor  Miriam Mints 
Karolinska Institutet 
Department of Women´s and Children´s Health 
Division of Obstetrics and Gynecology 
 
 
Co-supervisor(s): 
Emma Tham, MD, PhD 
Karolinska Institutet 
Department of Molecular Medicine and Surgery  
Division of Clinical Genetics 
 
Professor Annika Lindblom 
Karolinska Institutet 
Department of Molecular Medicine and Surgery 
Division of Clinical Genetics 
 
 
Professor Kristina Gemzell-Danielsson 
Karolinska Institutet 
Department of Women´s and Children´s Health 
Division of Obstetrics and Gynecology 
 
Opponent: 
Professor Mats Brännström 
University of Gothenburg 
Department of Obstetrics and Gynecology 
Sahlgrenska Academy 
 
 
Examination Board: 
Associate Professor Christer Borgfeldt 
University of Lund 
Department of Obstetrics and Gynecology  
 
 
Professor Angelica Lindén-Hirschberg 
Karolinska Institutet 
Department of Women´s and Children´s 
Health 
Division of Obstetrics and Gynecology 
 
Associate Professor Nina Larsson 
University of Lund 
Department of Clinical Genetics 
 
 
 
 
 
  
 
 
  
 
 
 
“The more you know, the more you know you don't know.” 
Aristotle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my beloved mother Theoni, my father 
Vasileios, my sister Polina 
and Valia 
  
ABSTRACT 
Endometrial carcinoma (EC) is the most common gynecological malignancy in Sweden and 
accounts for about 6 % of all female malignancies. The risk of EC increases with age and the 
majority of cases are diagnosed between age 50 and 60. Ninety percent of cases occur in 
women older than age 50. About 2% of EC may have a familial association related to Lynch 
syndrome (LS). About 80% of women with Cowden syndrome have the PTEN mutation, 
which increases their lifetime risk of developing EC. The benefit of EC surveillance among 
LS patients remains undetermined. Available studies are controversial concerning optimal 
age at which to initiate screening and screening modalities. 
Our first study explored the prevalence of LS, Cowden syndrome (CS) and hereditary breast 
ovarian cancer syndrome in consecutively diagnosed women with EC. In addition, we 
explored the possibility of a familial association between uterine cancer and other specific 
malignancies. In all, we included 481 consecutively diagnosed cases of endometrial cancer. 
We used the Swedish Cancer Registry to confirm all diagnoses, as well as for a reference 
population for the years 1970 and 2010. We conducted mutation analyses on all families who 
met criteria for the syndromes referred to above to identify potential causal genes. Our study 
demonstrated familial clustering among relatives of our index EC cases; EC prevalence was 
twice as high in our study population as in the cancer population in Sweden at large (6% vs 
4% and 3%). In addition, we identified LS in 1.5% of all women. No BRCA1 and BRCA2 
mutations were identified. No families fulfilled the CS criteria. Among all the LS families in 
which mutation could be verified, only one had previously been diagnosed. Moreover, we 
found that onset of cancer at a young age in family members of EC patients and diagnosis of 
multiple malignancies in the same patient lend support to the concept of hereditary uterine 
cancer syndromes. 
In study II, 54 Cowden syndrome-like families were identified from consecutively diagnosed 
EC patients. PCR and DNA sequencing analysis were carried out on genomic DNA to 
amplify all nine PTEN gene exons. Since we identified no germline mutations or 
polymorphisms, the implication is that these must be rare among CS-like families. Therefore 
strict Cowden syndrome criteria should be applied to identify CS patients. 
Our third study involved a retrospective nationwide study of 170 women with Lynch 
syndrome. We gathered data on all diagnostic methodology employed for gynecological 
screening of LS and prophylactic surgery, including age at surgery. In all, 86 of the 117 
women who were eligible for screening complied with the screening program. Gynecological 
surgery was carried out on 43 women prior to diagnosis with LS, for which reason they were 
inappropriate for screening. A lower incidence of cancer was found in the screened group 
than in the non-screened group. EC was diagnosed by endometrial biopsy in a large number 
of cases. In addition, the incidence of cancer was significantly reduced by prophylactic 
surgery. 
In conclusion, the results from our studies will improve both characterization of EC and 
family screening while expanding genetic counseling, and thereby help to prevent 
endometrial cancer in high-risk patients by enrolling them in EC prevention programs before 
endometrial cancer develops. Our results will improve routine procedures used to investigate 
families and surveillance programs for patients at high risk. Such patients can then be offered 
a choice between participation in screening programs or surgery for prophylactic purposes. 
According to our results, LS patients should be screened for gynecological cancer with 
transvaginal ultrasound (TVUS) and endometrial biopsy (EB) by age 30-35. Once high-risk 
women have completed childbearing, prophylactic surgery should be made available. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
POPULÄRVETENSKAPLIG SAMMANFATNING 
Livmodercancer/ endometriecancer (EC) är den fjärde vanligaste tumörformen hos kvinnor 
och utgör ca 6% av all kvinnlig cancer, vilket motsvarar ca 1400 fall/år i Sverige. 
Livstidsrisken för insjuknande är 2% i den totala befolkningen. Från 1960 har det skett en 
gradvis ökning av antalet nya fall: andelen gynekologiska cancerfall som utgörs av EC har 
stigit till 40 %. Risken för EC ökar med åldern, och de flesta fallen diagnostiseras mellan 50 
och 60 års ålder. 90% av alla fall inträffar hos kvinnor äldre än 50 år. Mortaliteten i EC ligger 
på 7-10 per 100 000 kvinnor. Övervikt, högt blodtryck, fysisk inaktivitet, diabetes och 
ärftlighet är de mest välkända riskfaktorerna för utveckling av EC.  
Ärftlig EC utgör 5 % av alla rapporterade EC-fall. I ca 1-2 % av alla EC är tumören en del av 
ett cancersyndrom med ökad risk för cancer i andra organ såsom Lynch syndrom (LS) och 
Cowden syndrom (CS). 
LS, tidigare benämnd hereditary non-polyposis colorectal cancer, HNPCC, står för ca 1-2% 
av alla kolorektalcancerfall och EC-fall i Sverige, och för ca 9 % av all EC som uppkommer 
före 50 års ålder. Den ärvs autosomalt dominant och har en frekvens mellan 1: 660 till 1: 
2000. Kvinnor med LS har en 40 - 60% livstidsrisk att utveckla EC (lika stor risk som 
kolorektalcancer) och i ca hälften av fallen sker insjuknandet i EC före eventuellt 
kolorektalcancerinsjuknande. Medianåldern för insjuknande i EC hos personer med LS är 
mellan 46-62 års ålder. Man har även en ökad risk för andra tumörformer såsom ventrikel-, 
ovarial-, tunntarms- samt uretärcancer. LS orsakas av en nedärvd mutation från ena föräldern 
i någon av generna som kallas för DNA mismatch repairgenerna (MMR-genes); MLH1, 
MSH2, MSH6 eller PMS2. Dessa gener kodar för proteiner som tillsammans bygger upp ett 
avancerat proteinkomplex kallat MMR-komplexet. Detta proteinkomplex’ uppgift är att 
upptäcka och reparera baser som felaktigt satts in i cellens DNA-sträng vid kopiering av 
genomet, vilket är en grundförutsättning för att den genetiska informationen överförs på ett 
säkert sätt till de nya dottercellerna som bildas vid celldelning. Om inte dessa gener kan 
bygga upp ett välfungerande MMR-komplex uppstår oundvikligen en pålagring av nya 
stavfel i DNA-koden för varje ny kopiering av genomet som sker. De uppkomna sekvenserna 
av stavfel kallas för microsatelliter, och syns i laboratoriet om man jämför de felkopierade 
kromosomerna med sina rättskrivna motsvarigheter. När man ser kromosomer med 
förekomst av microsatelliter säger man att genomet är utsatt för microsatellitinstabilitet 
(MSI). Som en logisk följd av detta samband mellan MMR-genernas funktion och uppkomst 
av MSI, så testar man för mutationer i MMR-generna på rutin om MSI upptäcks i tumörceller 
för att eventuellt se om personen tillhör en LS-familj, vilket har stor betydelse både för den 
berörde individens egen risk att utveckla nya cancrar, men också för den personens 
släktingar. Dock har analys av MSI en låg känslighet och specificitet för att hitta LS-orsakade 
EC-fall, då även en stor del av de sporadiska EC-tumörerna också uppvisar MSI pga. 
nyuppkomna (somatiska) mutationer i samma MMR-gener, samt att de LS orsakade EC-
tumörerna inte regelmässigt alltid behöver uppvisa MSI. Denna svåra ekvation gör att det 
idag inte finns biologiska markörer som med säkerhet kan säga vilka kvinnor med EC som 
kan ha LS. För närvarande används Amsterdam II eller Bethesda kriterierna, för att med hjälp 
av klinisk information identifiera misstänkta fall av LS, vilket skärper specificiteten men 
lämnar sensitiviteten oberörd. Det råder även oenighet om hur ett gynekologiskt 
kontrollprogram för kvinnor med LS ska utformas; när är det bäst tid att starta kontrollerna 
för kvinnor med LS, vilka diagnostiska metoder ska ingå i dem, och hur ska man behandla 
patienterna på längre sikt för att minska deras cancerrisk? 
Cowden syndrom (CS) är en autosomalt dominant sjukdom som kännetecknas av flera 
hamartom i bröstet, sköldkörteln, colon, njurarna och livmoderslemhinnan. Den globala 
incidensen är 1: 250,000. Nedärvda mutationer i tumör-suppressorgenen PTEN bedöms vara 
ansvarig för mellan 35 till 80% av alla Cowden syndromfall. Förlust av PTEN aktivitet sker 
efter att man ärvt en muterad allel som åtföljs av en andra somatisk mutation av den normala 
allelen, vilket leder till förlust av proteinproduktens funktion med ökad fosforylering av 
viktiga signalproteiner i cellen som följd. Detta har en effekt på olika cellulära processer och 
signalvägar i cellen, såsom cellcykelprogression, metabolism, tillväxt, migration, invasion, 
angiogenes och apoptos.  
Diagnosen av CS baseras på de National Comprehensive Cancer Network (NCCN) 
kriterierna.Livstidsrisken för att utveckla EC hos de med CS är 21-28%, med högsta 
incidensen av fall vid 35-45 års ålder.  
Målsättningen med det aktuella projektet var att:  
1. Kartlägga ärftligheten hos kvinnor med EC för att kunna erbjuda förbättrade 
riskberäkningar och omhändertagandet av kvinnor med familjär EC.  
2.  Utvärdera och optimera nuvarande kontrollprogram för EC för att kunna erbjuda 
kvinnor med risk för EC ett evidensbaserat preventionsprogram.  
I den första studien undersökte vi frekvensen av Lynch syndrom, Cowden syndrom och 
ärftlig bröstcancer/ äggstockscancer syndrom bland kvinnor med livmodercancer. Vi 
undersökte också om det fanns en familjär koppling mellan livmodercancer och andra 
  
cancrar. 481 kvinnor med diagnostiserad livmodercancer ingick i studien. Alla familjer som 
uppfyllde de kliniska kriterierna för ovannämnda cancersyndrom erbjöds mutationsanalys i 
syfte att identifiera möjliga orsaksframkallande gener.  
Var sjätte kvinna som deltog i studien har haft åtminstone en nära släkting med 
livmodercancer som har insjuknat innan 50 års ålder. Prevalensen av LS i vår 
studiepopulation var 1,5%, och alla kvinnor utom en diagnosticerades med LS tack vara 
deltagande i studien. Då vi har kunnat påvisa en ökad förekomst av livmodercancer i vår 
studiepopulation jämfört med den svenska befolkningen (6% mot 3%) kan dessa resultat tyda 
på ett ärftligt livmodercancersyndrom skilt från LS. 
I den andra studien identifierade vi 54 Cowden syndrom-liknande familjer bland kvinnor med 
livmodercancer. Med PCR och DNA-sekvenseringsanalys undersökte vi DNA från deras 
friska celler för att amplifiera alla nio exoner av PTEN-genen. Inga nedärvda mutationer eller 
polymorfismer identifierades, vilket tyder på att någon egentlig nedärvning från den tidigare 
generationen är sällsynt i CS-liknande familjer med livmodercancer. 
Den tredje studien vände sig till alla kvinnor med konstaterat Lynch syndrom 
hemmahörandes i Syd- och Mellansverige. 170 kvinnor inkluderas i studien. Vi har samlat 
uppgifter som inkluderade alla diagnostiska metoder som används för gynekologisk kontroll 
för dessa kvinnor, och eventuell profylaktisk kirurgi. Resultaten visade på en betydligt lägre 
(15%) cancerförekomst hos de kvinnor som deltagit i kontrollerna jämförande med 81% för 
de som inte deltagit i ett kontrollprogram. 13 fall av livmodercancer upptäcktes hos kvinnor 
som deltog i gynekologiska kontroller varav användande av biopsi från livmoderslemhinna 
var avgörande för att upptäcka dem på kontrollbesöken innan symptom utvecklades. Två fall 
av äggstockscancer hittades med ultraljud. På lång sikt var profylaktiskt bortagande av 
livmoder och äggstockar den enda faktorn som tydligt sänkte cancerförekomsten hos kvinnor 
med LS.  
Projektet har stor betydelse för hälso- och sjukvården. Våra resultat kommer innebära en 
förbättrad karakterisering av livmodercancer som diagnos, samt leda till en förbättrad 
släktutredning, där fler kommer att erbjudas genetisk rådgivning med möjlighet att inkludera 
alla kvinnor med ökad risk i preventionsprogram för EC och associerade tumörer redan innan 
de (eller någon annan släkting) utvecklar kliniska symtom av sitt syndrom. Projektet kommer 
att leda till förbättrade rutiner på kvinnokliniken vad gäller släktutredningar och 
kontrollprogram för riskindivider. De som har ärvt den sjukdomsorsakande mutationen kan 
då erbjudas profylaktisk kirurgi och/eller kontrollprogram. 
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1 INTRODUCTION 
1.1 ENDOMETRIAL CANCER 
Endometrial cancer (EC), which represents about 6% of all malignancies in women, is the 
most common gynecological malignancy in the developed world (National Board of Health 
and Welfare, 2012) (Burke et al., 2014). In addition, as the fourth most common form of 
cancer overall, about 3% of mortality from cancer is attributable to EC (Murali et al., 2014). 
There is an estimated 2-3% lifetime risk of developing EC (Salvesen et al., 2012), with a 
higher risk among Caucasian (2.88%) women than among African-American women (1.69%) 
(Burke et al., 2014). Endometrial cancer has steadily increased and annual incidence is 
currently estimated at 19-24 cases per 100,000 women (Murali et al., 2014). Mean age at 
diagnosis is about 60 years (Murali et al., 2014) (Sorosky et al., 2012) and fewer than 10-15% 
of cases are diagnosed prior to age 50 (Sorosky et al., 2012) (Burke et al., 2014). 
Significant risk factors include obesity, hypertension, nulliparity, anovulation, diabetes 
mellitus and polycystic ovarian syndrome (PCOS) (Haidopoulos et al., 2010) (Bansal et al., 
2009), also infertility and early age at menarche (Burke et al., 2014), as well as exposure to 
exogenous estrogens and tamoxifen (an estrogen receptor antagonist in breast tissue), when 
used for chemoprevention of breast cancer (Sorosky et al., 2012) (Burke et al., 2014). Factors 
that reduce risk of EC include high parity, oral contraceptives, progesterone-releasing IUDs 
and smoking (Murali et al., 2014) (Burke et al., 2014). Familial accumulation may occur in 
about 5% of cases (Olson et al., 2009). 
 
1.1.1 Classification 
Adenocarcinomas arising from epithelial cells account for up to 90% of endometrial 
carcinomas, including serous, endometrioid and clear cell tumors, which can be subdivided 
into two distinct types (Murali et al., 2014) (Sorosky et al., 2012) (Bansal et al., 2009). Type I 
tumors, which account for 70-80% of all endometrial cancers, mainly afflict younger, obese, 
pre- and perimenopausal women. Morphologically, type I is an endometrioid cancer. 
Unopposed estrogen stimulation contributes to estrogen-dependent hyperplasia, which 
precedes development of endometrial cancer in most type I tumors. These generally low-
grade tumors are moderately to highly differentiated and carry a relatively good prognosis 
(Sorosky et al., 2012) (Murali et al., 2014) (Salvesen et al., 2012). 
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Type II tumors, which account for up to 10% of cases (Murali et al., 2014), typically show 
serous or clear cell morphology and are usually found in older, postmenopausal women. They 
arise directly from atrophic endometrium without hyperplasia (Sorosky et al., 2012) (Murali 
et al., 2014). These tumors, which are unrelated to estrogen stimulation, are believed to 
develop from a malignant lesion referred to as intraepithelial carcinoma. Type II tumors are 
characterized by higher grade and poor differentiation (Sorosky et al., 2012) (Murali et al., 
2014) (Salvesen et al., 2012), and are therefore more aggressive (Sorosky et al., 2012) 
(Murali et al., 2014) (Salvesen et al., 2012). 
 
1.1.2 Molecular Characterization 
In addition to clinical and morphological differences, type I and type II tumors also differ at 
the molecular level, where they display different genetic alterations (Figure 1). The most 
commonly altered gene in type I EC is the PTEN tumor suppressor gene. Up to 80% of 
endometrial carcinomas and 55% of precancerous lesions (O’Hara et al., 2012) (Bansal et al., 
2009) demonstrate PTEN inactivation due to either somatic mutations or loss of 
heterozygosity (LOH) (Doll et al., 2008). 
 
Figure 1: Dualistic model of endometrial carcinoma progression highlighting genetic 
abnormalities at the molecular level in both type 1 and type 2 endometrial cancers. Reprinted 
from Doll et al., Journal of Steroid Biochemistry & Molecular Biology 2008, with permission 
from Elsevier (Doll et al., 2008). 
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Up to 40% of endometrial carcinomas display microsatellite instability (MSI) (O’Hara et al., 
2012) (Bansal et al., 2009) (Doll et al., 2008), which is caused by epigenetic silencing of the 
DNA mismatch repair gene (MMR) MLH1 via promoter methylation (O’Hara et al., 2012). 
Mutations have been reported for other genes in type I EC including KRAS, PIK3CA and 
CTNNB1 (beta-catenin), occurring as often as 30%, 36% and 40% of the time, respectively 
(Salvensen et al., 2012) (O’Hara et al., 2012) (Bansal et al., 2009) (Sorosky et al., 2012). 
Type I tumors are generally diploid and hormone-receptor positive (Salvensen et al., 2012). 
Dysregulation of the PI3K-PTEN-AKT signal transduction pathway in response to altered 
expression of PTEN and mutations in PIK3CA affects the molecular mechanisms of cell 
growth and proliferation, as well as survival and apoptosis (O’Hara et al., 2012) (Bansal et 
al., 2009). 
Aneuploidy is common in type II tumors and as many as 90% of serous tumors exhibit TP53 
mutations, which cause accumulation of cells with damaged DNA (O’Hara et al., 2012) 
(Bansal et al., 2009). Other mutations that commonly occur in type II tumors include 
CDKN2A/p16, HER2/ERBB2 amplification and inactivation of E-cadherin (O’Hara et al., 
2012) (Bansal et al., 2009) (Doll et al., 2008) (Salvensen et al., 2012), which impact cell 
growth, cell signaling and cell motility, respectively (Bansal et al., 2009). 
 
1.1.3 Diagnostics, surgical staging, treatment 
Abnormal uterine bleeding, including postmenopausal bleeding, is the most common sign of 
EC. The diagnosis can be confirmed through transvaginal ultrasound (TVUS) with 
endometrial biopsy (EB) or by dilatation and curettage (D&C) (Sorosky et al., 2012, SGO 
Clinical Practice et al., 2014). When endometrial sampling yields negative results, 
hysteroscopy can be a particularly useful technique, especially when symptoms persist or for 
guided EB (Sorosky et al., 2012) (Burke et al., 2014). 
Diagnosis is made through histopathological examination of endometrial biopsies. Magnetic 
resonance imaging (MRI) is superior to both computed tomography (CT) and ultrasound for 
determining tumor spread and elucidating the extent of myometrial and cervical invasion. 
Another promising technology is 18F- positron emission tomography (PET) –CT, which can 
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reveal metastatic lymph nodes, making it useful for post-therapy surveillance (Sorosky et al., 
2012) (Salvesen et al., 2012). 
The International Federation of Gynecologists and Obstetricians (FIGO) recommends 
surgical staging of EC in which surgical stage is based on tumor size and location, as outlined 
in table 1 (Pecorelli et al., 2009) and presented in figure 2. 
FIGO stage Extension of tumor 
Stage I* 
IA* 
IB* 
Tumor confined to the corpus uteri 
No or less than half myometrial invasion 
Invasion equal to or more than half of the myometrium 
Stage II* Tumor invades cervical stroma, but does not extend beyond the uterus 
Stage III* 
IIIA* 
IIIB* 
IIIC* 
IIIC1* 
IIIC2* 
Local and/or regional spread of the tumor 
Tumor invades the serosa of the corpus uteri and/or adnexae 
Vaginal and/or parametrial involvement 
Metastases to pelvic and/or para-aortic lymph nodes 
Positive pelvic lymph nodes 
Positive para-aortic lymph nodes with or without positive pelvic lymph 
nodes 
Stage IV* 
IVA* 
IVB* 
Tumor invades bladder and/or bowel mucosa, and/or distant metastases 
Tumor invasion of bladder and/or bowel mucosa 
Distant metastases, including intra-abdominal metastases and/or inguinal 
lymph nodes 
*Either Grade 1, Grade 2 or Grade 3 
*Positive cytology requires separate reporting, with no change in stage 
Table 1: FIGO stages for endometrial cancer. Reprinted from Pecorelli et al., International 
Journal of Gynecology and Obstetrics, with permission from Elsevier (Pecorelli et al., 2009). 
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Surgery, including hysterectomy and bilateral salpingo-ophorectomy, is the currently 
accepted curative treatment for EC. Staging is carried out using peritoneal washing as well as 
pelvic and para-aortic lymphadenectomy (DeLeon et al., 2014). Advanced FIGO stage 
disease and certain rare high-risk histological subtypes require more extensive surgery 
(Sorosky et al., 2012). Stratification of patient risk depends on histological type, DNA ploidy 
status, myometrial invasion and lymph node involvement, as well as degree of metastatic 
involvement (Salvesen et al., 2012). 
 
 
Figure 2: Diagram depicting the various stages of uterine cancer. Image source: Cancer 
Research UK / Wikimedia Commons. 
Key signaling pathway changes with other potential biomarkers are currently being validated 
for their prognostic value (Salvesen et al., 2012). 
Postoperative radiation therapy (vaginal brachytherapy or external beam radiation) and/or 
chemotherapy are limited to patients who are at high risk of local recurrence (Sorosky et al., 
2012) (Burke et al., 2014) and/or advanced stage disease (Sorosky et al., 2012) (DeLeon et 
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al., 2014) (Salvesen et al., 2012) (Burke et al., 2014). 
 
1.2 HEREDITARY FACTORS AND ENDOMETRIAL CANCER 
1.2.1. Lynch Syndrome 
1.2.1.1 History 
The history of hereditary nonpolyposis colorectal cancer, also known as Lynch syndrome 
(LS/HNPCC), can be traced to 1895 when University of Michigan pathologist Dr. Aldred 
Warthin was inspired to investigate the family history of his seamstress, due to an abundance 
of various cancers (gastric, colonic or uterine cancer) in her family (Kastrinos et al., 2014) 
(Sehgal et al., 2014). His work, in which he referred to her family as “Family G,” was 
published in 1913 and after additional research, he hypothesized about the “influence of 
heredity on cancer” (Sehgal et al., 2014). In 1966 Dr. Henry Lynch described two families 
with colon, gastric and endometrial cancer and proposed a new familial cancer syndrome, 
ultimately called Lynch syndrome in 1984 (Kastrinos et al., 2014) (Martín-Lopez et al., 
2013). This syndrome was termed HNPCC to distinguish it from familial adenomatous 
polyposis (FAP), since colorectal adenomatous polyps were fewer  (Kastrinos et al., 2014) 
and extracolonic cancers were present (Martin-Lopez et al., 2013). 
 
1.2.1.2 Etiology-Cancer risks 
 LS displays an autosomal dominant pattern of inheritance with an incidence ranging from 
1:200 to 1:660 (de la Chapelle, 2005) and accounts for up to 4% of all colorectal cancers 
(Tutlewska et al., 2013) and 2% of all cases of uterine cancer; among women < age 50 
prevalence may be as high as 9% (Garg et al., 2009). Not until 1993 were mutations in the 
DNA mismatch repair (MMR) genes MLH1 (Mut L homologue), MSH2, MSH6 (Mut S 
homologues) and PMS2 (postmeiotic segregation, a Mut L homologue) found to be the cause 
of LS (Kastrinos et al., 2014) (de la Chapelle, 2005) (Walsh et al., 2010) (Lim et al 2010) 
(Sehgal et al., 2014). Meanwhile, although not a mismatch repair gene, the epithelial cell 
adhesion molecule gene (EPCAM) was recently identified as the gene that may cause LS 
(Tutlewska et al., 2013). 
 
Mutations in MLH1 and MSH2 account for 90% of all mutations associated with LS (50% 
MLH1 and 40% MSH2), while MSH6 mutations account for 7-10%, PMS2 <5% and EPCAM 
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1-3% (Kohlman et al., 2014) (Tutlewska et al., 2013) (Cohen et al., 2014). Moreover, lifetime 
risks linked to LS may vary depending on the specific gene mutations involved (Kastrinos et 
al., 2014) (Cohen et al., 2014) (Barrow et al., 2013). 
 
The risk of developing colorectal cancer (up to age 70) lies between 40-80% in carriers of 
MLH1 and MSH2, with a mean age at onset of 40-61 years; for MSH6 the risk is 22% (mean 
age 54) and for PMS2 up to 20% (mean age 61-66). Regarding endometrial cancer, lifetime 
risks vary from 40 to 60% for MLH1, MSH2 and MSH6 carriers (mean age of onset 47-62), 
while for PMS2 the risk can be as high as 15% (mean age 50). (Kastrinos et al., 2014) (Cohen 
et al., 2014) (Barrow et al., 2013) (Kohlman et al., 2014) (Tafe et al., 2014). Endometrial 
cancer is often regarded as the sentinel cancer in women with Lynch syndrome (Cohen et al., 
2014) (Lu et al., 2005). 
 
Lifetime risk of developing ovarian cancer is highest in carriers of the MSH2 mutation, 
followed by MSH6 and MLH1, with estimated risks falling between 12 and 24% (Gerritzen et 
al., 2009) (Lu et al., 2005). Lifetime risks among the general population are 4.8% for 
colorectal cancer, 2.55% for endometrial and 1.4% for ovarian cancer (Kastrinos et al., 2014) 
(Cohen et al., 2014) (Barrow et al., 2013) (Kohlman et al., 2014). Concomitant ovarian and 
endometrial cancers are common among mutation carriers (Cohen et al., 2014), who are also 
at greater risk of gastric, ovarian, small intestine, urethral, hepatobiliary, skin (sebaceous 
gland tumors), brain and pancreas cancers (Cohen et al., 2014). 
 
Researchers have also investigated the link between breast cancer and LS, but so far none 
has been found. Nevertheless, breast tumors have occurred in some LS patients with MMR 
deficiency, implying a possible link. In general, however, there is no significant difference 
in incidence of breast cancer among LS patients compared with the population at large 
(Cohen et al., 2014) (Win et al., 2013). 
 
1.2.1.3 Mismatch repair mechanism; deletions in the EPCAM gene 
The mismatch repair mechanism (MMR) is a proofreading system of the DNA replication 
process. The system identifies potential sites of DNA strand distortion around mismatched 
base pairs, as well as insertion-deletion loops (Kastrinos et al., 2014) (Guillotin et al., 
2014). Two heterodimer proteins, known as MutL and MutS, form the MMR system. The 
two homologues of MutS, MSH2 and MSH6, are able to recognize and bind to incorrectly 
matched base pairs. MutL, with its two homologues MLH1 and PMS2, links up with MutS 
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and scans for single strand breaks in the preceding DNA sequence. When such breaks are 
found, MutL recruits exonuclease 1(Exo1) to catalyze removal of the daughter strand 
sequence up to and including the mutation where MutS resides. 
 
Replication protein A (RPA) stabilizes the single-stranded DNA, thereby preventing Exo1 
from undertaking further degradation. This process leaves behind a bare parental strand 
sequence with a large piece missing from the sequence of the daughter strand. Next the 
correct sequence is replaced in the missing daughter strand by DNA polymerase (Kastrinos 
et al., 2014) (Martín-Lopez et al., 2013), ligated by DNA ligase (Guillotin et al., 2014) 
(figure 3). 
 
 
 
 
 
Figure 3: Mismatch repair mechanism including recognition, excision and resynthesis of the 
replicated DNA strand, in which base-base mismatches and insertion-deletion loops have 
occurred. Reprinted from Guillotin et al., Experimental Cell research, with permission from 
Elsevier (Guillotin et al., 2014). 
 
Lynch syndrome is caused by loss of expression of one of the MMR proteins. Patients with 
LS inherit one germline mutation of one MMR gene. Dysfunction of one MMR gene 
results from somatic mutation or methylation (in MLH1), which culminates in tumor 
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development (Kastrinos et al., 2014) (Guillotin et al., 2014). Recent research has shown 
that one cause of LS in LS families that display deficient MSH2 protein expression is 
germline deletions of the last two exons of the EPCAM gene. The location of MSH2 is on 
chromosome 2 near the EPCAM gene. Deletions in the 3´ end of EPCAM allow additional 
methylation of the MSH2 gene promoter region, which reduces expression through a 
mechanism referred to as epigenetic silencing by promoter hypermethylation (Kastrinos et 
al., 2014) (Tutlewska et al., 2013). 
 
1.2.1.4 Histology and molecular characteristics 
When compared with sporadic carcinomas, colorectal cancer associated with Lynch 
syndrome demonstrates certain characteristics such as rapid progression from precancerous 
adenoma to cancer. Other characteristics include earlier onset of disease and more frequent 
involvement of the right colon. On the molecular level, these tumors display poor 
differentiation, tumor-infiltrating lymphocytes, mucinous cells and peritumoral lymphoid 
follicles (Cohen et al., 2013) (Tafe et al., 2014). 
 
Most Lynch syndrome endometrial cancers are characterized by endometrioid histology, 
although both serous and clear cell carcinomas may also occur (Cohen et al., 2014) (Tafe et 
al., 2013) (Wang et al., 2013). Endometrial cancers exhibiting MMR deficiency share 
specific morphologic characteristics, including tumor-infiltrating and peritumoral 
lymphocytes (Cohen et al., 2014); in addition, they may demonstrate poor differentiation and 
other inflammatory infiltration of the tumor site (Wang et al 2013). In LS-related EC, 
involvement of the lower uterine segment is more common than in sporadic EC (Wang et al., 
2013) (Tafe et al., 2014). 
 
Lynch syndrome-associated ovarian cancer may include all histological types (e.g., 
endometrioid, clear cell, mucinous and serous cancers), although the incidence of serous 
cancers is low (Cohen et al., 2014) (Nakamura et al., 2014). At the time of diagnosis, most 
ovarian cancers are stage I or II and are moderately or well-differentiated (Nakamura et al., 
2014). 
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1.1.2.5  Diagnosis of Lynch syndrome 
When making a diagnosis of Lynch syndrome, a detailed family history concerning all 
cancer, regardless of site (including extra-colonic cancers), is of paramount importance, after 
which a pedigree can be constructed (figure 4). Lynch syndrome should be suspected when a 
clustering of LS-associated tumors is found, especially when onset is at an early age, and 
where an autosomal dominant pattern of inheritance can be established (Lynch et al., 2009). 
 
 
 
Figure 4: Typical pedigree found in a Lynch syndrome family with an MSH2 mutation, with 
incidence of both colorectal and extracolonic cancers. Reprinted from Akoum et al., 
Hereditary Cancer in Clinical Practice 2009, 7:10, under the Creative Commons Attribution 
(CC-BY) license. 
 
The causative genes in Lynch syndrome may be identified by applying the Amsterdam 
Criteria I/II (Vasen et al., 1999) and the revised Bethesda guidelines (Seghal et al., 2014) 
(Lynch et al., 2009) (Kohlman et al., 2014) (table 2). Since the sensitivity of the Amsterdam 
II criteria ranges from 50 to 87% (Sjursen et al., 2010) for colorectal cancer but only 20-30 % 
for endometrial cancer (Lu et al., 2005) (Leenen et al., 2012), some Lynch syndrome families 
may be missed, especially regarding colorectal cancer (Manchada et al., 2009). Specificity is 
as high as 70% (Cohen et al., 2014). Patients with the MMR gene mutation may be missed up 
to 25% of the time when the Bethesda guidelines are applied (Seghal et al., 2014). 
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Amsterdam Criteria I 
At least three relatives with histologically verified colorectal cancer: 
1. One is a first-degree relative of the other two; 
2. At least two successive generations affected; 
3. At least one of the relatives with colorectal cancer diagnosed at <50 years of age; 
4. Familial adenomatous polyposis (FAP) has been excluded. 
Amsterdam Criteria II 
At least three relatives with an hereditary nonpolyposis colorectal cancer (HNPCC)-associated 
cancer [colorectal cancer, endometrial, stomach, ovary, ureter/renal pelvis, brain, small bowel, 
hepatobiliary tract, and skin (sebaceous tumors)]: 
1. One is a first-degree relative of the other two; 
2. At least two successive generations affected; 
3. At least one of the syndrome-associated cancers should be diagnosed at <50 years 
of age; 
4. FAP should be excluded in any colorectal cancer cases; 
5. Tumors should be verified whenever possible. 
Revised Bethesda Guidelines 
Colorectal tumors from individuals should be tested for MSI in the following situations: 
1. Colorectal cancer diagnosed in a patient who is <50 years of age. 
2. Presence of synchronous or metachronous colorectal, or other HNPCC-associated 
tumors regardless of age. 
3. Colorectal cancer with microsatellite instability-high (MSI-H) histology diagnosed 
in a patient who is <60 years of age. 
4. Colorectal cancer diagnosed in one or more first-degree relatives with an 
HNPCC-related tumor, with one of the cancers being diagnosed under age 50 years. 
5. Colorectal cancer diagnosed in two or more first- or second-degree relatives with 
HNPCC-related tumors, regardless of age. 
 
Table 2: Amsterdam Criteria I/II and revised Bethesda guidelines as used to identify patients 
with Lynch syndrome. Adapted from Sehgal et al., 2014, Genes under the Creative Commons 
Attribution License for open access from MDPI AG (Seghal et al., 2014). 
 
 
 
 12 
 
Microsatellites are small repetitive DNA nucleotide sequences (e.g. AAAAA or 
CGCGCGCG) that usually acquire errors in the presence of MMR dysfunction. Therefore, 
when tumors arise due to MMR gene dysfunction, a deviant number of microsatellite 
nucleotide repeats is found (compared with normal tissue). This is known as microsatellite 
instability (MSI), which can be identified by subjecting tumors from suspected Lynch 
syndrome patients to molecular tissue analysis to help make the diagnosis (Kohlmann et al., 
2014) (Ma et al., 2013). Both tumor and normal tissues are subjected to analysis to determine 
the extent of microsatellite instability; tumors may be characterized as being MSH-high 
(instability shown in two or more markers), MSI-low (instability shown in only one marker) 
or MS-stable (no instability). Up to 80% of colon adenomas associated with Lynch syndrome 
may be MSI-high. 
 
Certain limitations apply to MSI testing for EC. MSH6 mutations may be MSI-low or MS-
stable (Hampel et al., 2006), which can create problems when diagnosing Lynch syndrome in 
EC patients. Moreover, MLH1 promoter hypermethylation in sporadic cases of EC may result 
in MSI-high endometrial tumors (up to 75% of MSI-high cases in EC) (Tafe et al., 2014) (Ma 
et al., 2013). Other advantages to using MSI testing to aid in diagnosis of Lynch syndrome 
include: 1) effective in identifying tumors caused by MMR dysfunction, 2) little tissue 
required and 3) reproducible results (Kohlmann et al., 2014). 
 
In addition to the limitations mentioned above, MSI testing has other disadvantages. Testing 
is not universally available since it requires a lab equipped for molecular analysis and 
microdissection. In addition, this technique may not be cost-effective since MSI testing must 
be followed by molecular testing to identify the mutated genes (Kohlmann et al., 2014). 
 
Immunohistochemistry (IHC), with sensitivity of up to 92% (Ma et al., 2013) (Kohlmann et 
al., 2014), may also be used to evaluate the presence or absence of MMR gene protein 
expression in tumor tissue. Most hospital pathology labs are equipped for this test, which 
costs less than MSI testing and may allow identification of the specific gene mutation through 
targeted mutational analysis (Kohlmann et al., 2014). As with MSI testing, it must be 
determined whether MLH1 promoter hypermethylation or germline mutations are responsible 
for loss of MLH1 expression in EC. One disadvantage of IHC is the weak staining pattern 
often encountered in tissue sample preparation. Use of small tissue samples also makes this 
technique less reliable (Kohlmann et al., 2014) (Tafe et al., 2014) (Ma et al., 2013). 
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Various organizations have established guidelines for risk assessment, screening, genetic 
testing, treatment and surveillance of patients and families with LS, the largest of which is the 
National Comprehensive Cancer Network guidelines (Seghal et al., 2014) (Lynch et al., 
2009) (NCCN guidelines version 2.2013). 
Under current recommendations, MSI testing or immunohistochemistry should be carried out 
on all endometrial cancers (<70 years) (excluding MLH1 promoter hypermethylation in EC) 
and on all colorectal tumors (<70 years) to help identify LS (Vasen et al., 2013) (Seghal et al., 
2014). 
 
1.2.2 Cowden Syndrome 
A young woman named Rachel Cowden presented to the hospital in 1962 with cystic and 
ulcerative breast disease. In addition, she exhibited thyroid disease, papillomatous growths of 
the oral cavity and central nervous system lesions, as well as other unusual findings. Other 
members of her family were found to have similar disorders. Suspecting a new syndrome, her 
doctors named it after the patient (Mester et al., 2014). 
Cowden syndrome, with an incidence of 1:250,000, is a rare autosomal dominant disorder 
with incomplete penetrance and variable expressivity (Farooq et al., 2010). Typical findings 
include multiple hamartomas (especially cutaneous), macrocephaly and an increased risk for 
developing various cancers including breast, thyroid and endometrial carcinoma (Farooq et 
al., 2010), as well as renal cancer, colorectal cancer and melanoma (Mester et al., 2014) 
(Pilarsky et al., 2013). Facial trichilemmomas, papillomatous papules and acral keratosis are 
the most common mucocutaneous lesions. Lhermitte-Duclos disease (cerebellar 
hamartomas), is a component of Cowden syndrome and can manifest as headaches, cerebellar 
ataxia and visual disturbances, as well as increased intracranial pressure (Farooq et al., 2010). 
The diagnosis is made according to the National Comprehensive Network (NCCN) clinical 
criteria (NCCN guidelines, v1 2012) (table 3). Patients who demonstrate either some or a 
combination of typical characteristics, and who display the CS phenotype, while failing to 
strictly meet NCCN criteria, are referred to as Cowden syndrome-like patients. 
Different authors vary as to what criteria are required for the Cowden syndrome-like 
classification (Marsh et al., 1998) (Rustad et al., 2006) (Bennett et al., 2006) (Ni et al., 2008) 
(Orloff et al., 2013) (Tzortzatos, Aravidis et al., In press January 2015). 
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Pathognomonic criteria Major criteria Minor criteria 
 Adult Lhermitte-Duclos 
disease 
 Mucocutaneous lesions: 
 Facial trichilemmomas 
 Acral keratosis 
 Mucosal lesions 
 
 
 
 
 Breast cancer 
 Non-medullary 
thyroid cancer 
 Macrocephaly 
 (>97
th
 percentile) 
 Endometrial 
carcinoma 
 Benign thyroid 
lesions(goiter/nodules) 
 Mental 
retardation(IQ<75) 
 Hamartomas in the 
gastrointestinal canal 
 Lipomas 
 Fibrocystic breast 
disease 
 Fibromas 
 Genitourinary tumors 
(renal cancer) and 
malformations 
A diagnosis of CS can be made in an individual who meets one of the following criteria: 
1) Pathognomonic lesions alone given the presence of: 
 Six or more facial papules, three or more of which must be trichilemmoma or 
 Facial cutaneous papules and oral mucosal papillomatosis or 
 Oral mucosal papillomatosis and acral keratoses or 
 Six or more palmoplantar keratoses  
2) Presence of two major criteria, one of which must be macrocephaly 
3) Presence of one major plus three minor criteria 
4) Presence of four minor criteria 
 
Table 3: Clinical diagnostic criteria for Cowden syndrome (Adapted from NCCN guidelines 
v1, 2012). 
 
Cowden syndrome belongs to a group of diseases linked to germline mutations in the PTEN 
gene, which along with Bannayan-Riley-Ruvalcaba syndrome (BRRS), Lhermitte-Duclos 
disease and autism disorders associated with macrocephaly constitute the PTEN hamartoma 
tumor syndrome (Mester et al., 2014). BRRS, a childhood disorder, is also characterized by 
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macrocephaly, hamartomatous intestinal polyps, lipomas and pigmented macules of the 
penis, intellectual disability/developmental delay (Farooq et al., 2010) (Mester et al., 2014) 
(Pilarski et al.,2013). 
Earlier reports indicated that as many as 80% of patients who met the clinical criteria for 
Cowden syndrome had PTEN germline mutations (Farooq et al., 2010); however, more recent 
research (Pilarski et al., 2013) indicates that PTEN mutations occur in up to 35% of CS 
patients and in 23-42% of patients who fulfill the BRRS criteria. In classical CS, most PTEN 
germline mutations affect exon 5 (up to 40%) as well as exons 7 and 8 (Orloff et al., 2008). 
Large deletions in the PTEN gene have only been found in 1% of cases, while about 10% of 
all patients with classic CS demonstrate mutations in the promoter region (Zhou et al., 2003). 
Among CS and CS-like patients without PTEN involvement, mutations in succinate 
dehydrogenase genes (SDHB/C/D), which exert an effect on mitochondrial function, may be 
responsible for activation of pathways that are similar to those affected by PTEN mutations 
(Ni et al., 2008). Other mutations have been noted in the RASAL1 (RasGTPase activating 
protein gene) tumor suppressor gene, which affects thyroid tumorigenesis (Ngeow et al., 
2014), the PIK3CA and AKT1 genes (Orloff et al., 2013), as well as hypermethylation of the 
KILLIN tumor suppressor gene that is occupies the same location on the chromosome as the 
PTEN gene. The KILLIN gene, which is transcribed in the opposite direction from PTEN, is 
regulated by p53 and plays a role in cell cycle arrest (Bennet et al.,v2010) (Mester et al, 
2014). 
In women, the PTEN germline mutation is associated with an 85% lifetime risk for 
developing breast cancer, as well as a 34% risk for renal cancer and a 28% risk of developing 
endometrial cancer, 35 % thyroid cancer  (Tan et al., 2012) (Mester et al., 2014). The 
elevated risk of developing EC begins when women reach their late 30s to early 40s (Tan et 
al., 2012) (Nieuwenhuis et al., 2014) (Bubien et al., 2013). 
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1.2.3 PTEN gene 
The PTEN gene (phosphatase and tensin homologue) is localized to chromosome 10q23.3. 
This 9-exon tumor suppressor gene encodes for a protein consisting of 403 amino acids 
(Farooq et al., 2010) (Nakanishi et al., 2014) (Black et al., 2005). It exerts a negative 
regulatory effect on the phospho-inositide 3-kinase (PI3K)/AKT/mTOR pathway (figure 3) 
by decreasing the activity of kinases (PDK-1, AKT, mTOR, S6K1) found downstream from 
PI3K, through conversion of phosphatidylinositol 3,4,5-triphosfate (PIP3) into 
phosphatidylinositol 4,5-bisphophate (PIP2) (Nakanishi et al., 2014) (Hollander et al., 2011). 
When PTEN activity is reduced or lost, the resultant increase in phosphorylation of several 
crucial cellular proteins (figure 3) (Hollander et al 2011) may impact various processes 
including cell cycle progression, metabolism, translation, growth, migration, invasion, 
angiogenesis, apoptosis and cell survival (Farooq et al., 2010) (Hollander et al 2011) 
(Nakanishi et al., 2014). 
 
 
Figure 5: PTEN phosphatase activity and its interaction with various signaling pathways 
through the PI3K-AKT/mTOR pathway. Reprinted from Hollander et al., Nature 
reviews/Cancer, with permission from Macmillan Publishers Ltd (Hollander et al., 2011). 
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Somatic PTEN alterations are common in a variety of sporadic tumors. Such mutations can 
be found in breast, endometrial (up to 35-55% of sporadic endometrial carcinomas) (Peterson 
et al., 2012), thyroid, prostate and renal cancers, as well as in melanomas (Tan et al., 2012) 
(Hollander et al., 2011) (Farooq et al., 2010). PTEN inactivation may be caused by gene 
deletions, small insertions and mutations or alterations that may occur throughout the entire 
coding region, most commonly in exon 5 (Hollander et al., 2011). 
 
1.2.4 Hereditary breast and ovarian syndrome 
The cause of hereditary breast ovarian cancer syndrome (HBOC) is through mutation of the 
BRCA1 and BRCA2 genes (Lynch et al., 2013). Up to 10% of all breast cancer (Kobayashi et 
al., 2013) and up to 15% of ovarian cancers (Meaney-Delman et al., 2013) can be attributed 
to this syndrome. Lifetime risk among mutation carriers of developing breast cancer is 45-
80%. Among BRCA1 carriers, there is a 45-60% lifetime risk of developing ovarian cancer, 
while the corresponding figures for BRCA2 carriers is 11-35% (Paul et al., 2014). 
When HBOC is suspected in Sweden, the following criteria are used in counseling situations 
to test for BRCA1 and BRCA2 mutations: 
1) At least three cases of breast cancer in first-degree relatives, one of whom was under the 
age of 50 at the time of diagnosis 
2) Two first-degree relatives with breast cancer, one before the age of 40 years 
3) One case of breast cancer before 35 
4) Any combination of breast cancer and ovarian cancer in a family regardless of age 
5) One case of ovarian cancer before age 45 
(The Swedish Society of Medical Genetics, (SFMG), Guidelines 2014) (von Wachenfeldt et 
al., 2007). 
BRCA1 and BRCA2 mutation carriers play no role in the development of endometrial cancer, 
except among patients who have used tamoxifen (Shai et al., 2014). However, a recent 
association has been implied between serous a endometrial cancer and BRCA1 gene 
mutation, which suggests a possible association with HBOC syndrome (Pennington et al., 
2013). 
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1.2.5 Gynecologic surveillance in Lynch syndrome 
Controversy persists regarding the benefit of screening Lynch syndrome patients for 
gynecological cancer and what diagnostic modalities to employ (Auranen et al., 2011) (Vasen 
et al., 2013). Surveillance is recommended for early detection of gynecological cancer 
because of the elevated risk for endometrial and ovarian cancer (Barrow et al., 2013). 
Current recommendations suggest beginning surveillance at age 30-35 years with an 
annual/biannual gynecologic examination, to include transvaginal ultrasound, endometrial 
biopsy (Barrow et al., 2013) (Vasen et al., 2013) and possibly CA-125 and hysteroscopy 
(Barrow et al., 2013). Inclusion of endometrial sampling in the recommended screening 
program may entail some discomfort (Elmarsy et al., 2009) that could discourage patients 
from being compliant with rechecks and gynecological screening (Crispens et al., 2012). 
One regimen that has recently been tested combines colonoscopy with endometrial sampling 
under sedation, thereby reducing pain, discomfort and anxiety. Results are promising, but 
have not yet been adopted as standard clinical practice (Huang et al., 2011). 
Prophylactic hysterectomy and bilateral salpingo-oophorectomy (BSO) should be offered to 
LS mutation carriers (Vasen et al., 2013), for whom this strategy has proven effective to 
minimize the risk of developing gynecological cancer (Schmeler et al., 2006). According to 
current international recommendations the procedure should be timed with completion of 
childbearing (> 40years) after informing the patient about the risks and benefits of surgery 
(Vasen et al., 2013). Both prophylactic gynecological surgery and planned colorectal surgery 
may be carried out at the same time (Vasen et al., 2013). 
Both reproductive and clinical genetic counseling should be offered to young patients with 
Lynch syndrome who have not yet completed childbearing in order to discuss options related 
to prenatal and/or preimplantation diagnosis (Cohen et al., 2014). 
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1.2.6 Family history 
A variety of studies have addressed the possibility of a familial association with respect to 
EC. Increased risk of developing EC at a younger age (<55 years) is found among women 
whose first-degree relatives have been diagnosed with this disease (Parazzini et al., 1994) 
(Lucentaforte et al., 2009). A family history of colorectal and ovarian cancer in first-degree 
relatives has been linked to EC (Lucentaforte et al., 2009) (Hemminki et al., 2004). In 
addition, increased risk of endometrial cancer (Kazerouni et al., 2002) has been found to be 
associated (von Wachenfeldt et al., 2007) with a history of personal or familial breast cancer. 
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“The only true wisdom is in knowing you know nothing.”  
Socrates
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2 AIMS OF THE THESIS 
This thesis aims to expand our current understanding of EC and to analyze hereditary factors 
among women with EC to ultimately improve risk assessment and surveillance of women at 
risk for familial EC. Furthermore, we aimed to identify possible disease-causing genes in 
families with suspected high-risk genes.  Another aim was to evaluate and optimize current 
EC screening programs in order to create an evidence-based EC prevention program for 
women at risk. 
Specific aims for each paper: 
I. To investigate the frequency of hereditary uterine cancer syndromes, including 
LS, Cowden syndrome and hereditary breast and ovarian cancer, among uterine 
cancer patients in Sweden. To study what familial association might exist between 
uterine cancer and other selected cancers. 
II. To examine the prevalence of germline PTEN mutations in a significant 
proportion of Cowden and Cowden-like families of endometrial cancer patients. 
III. The aim of this study is to examine how and with what kind of diagnostic 
modalities the gynaecological surveillance of LS patients is performed in Sweden.  
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3 MATERIAL AND METHODS 
3.1  PAPER  I 
3.1.1 Study design 
The Department of Obstetrics and Gynecology, Karolinska University Hospital, 
Stockholm, Sweden serves as the referral center for all cases of uterine cancer in 
Stockholm County. 
Of the 890 patients operated for uterine cancer between January 2008 and March 2012 
who were invited to participate in the current study, 481 accepted (index patients). We 
obtained information regarding diagnosis and age at onset for the various cancers (i.e., 
colorectal, breast, ovarian and other cancers in the index patient, as well as in her first and 
second-degree relatives, including first cousins), height, weight, parity, history of diabetes 
mellitus, hormone replacement therapy, lipid-lowering drugs, and prior cancer diagnoses. 
All information was updated at the end of the study period using the patient’s medical 
records and the Swedish Cancer Registry. 
A blood sample for DNA extraction was taken from all patients in accordance with 
Registry of Endometrial Cancer biobank procedures in Stockholm, Sweden. Telephone 
interviews were undertaken to obtain relevant information concerning first- and second-
degree relatives and first cousins of index patients. We recorded relevant information 
regarding current age or age at death, type of cancer and age when cancer was diagnosed. 
All diagnoses (for both index patients and their relatives) were histopathologically 
verified. We also examined data from the Swedish Cancer Registry, medical records 
and/or death certificates. 
Pedigrees were constructed for each patient using the information collected, after which 
all pedigrees were examined for the presence of Lynch syndrome, Cowden syndrome and 
hereditary breast and ovarian cancer in accordance with the Amsterdam II criteria (Seghal 
et al., 2014), the National Comprehensive Cancer Network guidelines (NCCN guidelines, 
v1 2012) and HBOC criteria (von Wachenfeldt et al., 2007), respectively. 
We followed current standard procedures to screen mutations for causative genes, 
including MLH1, MSH2.MSH6, BRCA1 and BRCA2. Pedigrees were also assessed for 
occurrence of cancer among close relatives, especially focusing on putative hereditary 
endometrial cancer, as well as colorectal, breast and ovarian cancer. 
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When examining family history of cancer among participating patients we only linked either 
the maternal or paternal family, depending on which side had the most cancers, to each index 
patient. Among family members who had > one cancer, each type of cancer was counted 
individually. 
 
3.1.2 Reference population 
All physicians and pathologists report all new cancer cases to the Swedish Cancer Registry, 
which was founded in 1958. The registry was used to verify the various cancer diagnoses 
among both index patients and their family members, and served as a reference population 
for this study. The population of Sweden was 8.08 million (2.621.732 > 50years) in 1970 and 
9.4 million (3.492.146 >50 years) in 2010, at which points in time the total numbers of cases 
of cancer reported annually to the Cancer Registry were 28,594 and 54,342, respectively. 
 
3.2  PAPER  II 
3.2.1 Study design 
We selected participants from the cohort of patients with endometrial cancer who had surgery 
between January 2008 and March 2012 and who also participated in study no. I. The 
pedigrees created by the process outlined in study no. I, were all assessed for possible 
Cowden syndrome and Cowden syndrome-like families. 
Cowden syndrome-like families can be defined by the presence of at least one case of 
endometrial cancer and one case of breast cancer, in addition to at least one additional tumor 
associated with Cowden syndrome (endometrial, breast, thyroid, colon, or renal cancer) in a 
given individual, or among first-degree relatives. We applied NCCN guidelines (NCCN 
guidelines, v1 2012) and the definition for Cowden syndrome-like families (as presented 
above and in paper II) (Tzortzatos, Aravidis et al., In press 2015) to assess whether any 
patients met the criteria for Cowden syndrome and/or CS-like families. 
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3.2.2 Touchdown PCR/ DNA sequencing 
Genomic DNA was extracted from peripheral blood leucocytes following standard procedure 
at the Department of Clinical Genetics, Karolinska University Hospital (MagneSil Genomic, 
large volume system, Promega, Madison, WI, USA in a Tecan robot serial no. 904004850, 
Männedorf, Switzerland). All nine PTEN gene exons, including adjacent introns, were then 
amplified by subjecting the extracted genomic DNA to polymerase chain reaction. We used 
the Primer3Plus platform online tool (http://www.bioinformatics.nl/cgi-
bin/primer3plus/primer3plus.cgi/) to design the PCR primers and produce amplicons ranging 
in size from 230 to 399 bp, which also contained the area of interest. For verification that 
each primer pair would generate its own unique amplicon from the entire genomic DNA 
sequence the UCSC In-Silico PCR tool was used (http://genome.ucsc.edu/cgi-
bin/hgPcr?command=start). We used AmpliTaq Gold DNA Polymerase
TM 
(Roche Molecular 
Diagnostics, Pleasanton, CA, USA) to amplify each fragment in a 25 μl final PCR volume 
that contained both the pair of primers at a concentration of 10 μM and 50 ng of DNA 
template from each patient. PCR reactions were carried out in 96-well PCR plates (Bio-Rad, 
Hercules, CA, USA) using a 2720 thermal cycler (Applied Biosystems Foster City, CA, 
USA) or a DNA Engine Tetrad
R
 2 Peltier Thermal Cycler (Bio-Rad, Hercules, CA, USA). 
Using the temperature independently designated based on the melting temperatures (Tm) for 
each primer pair, we applied a “touchdown” PCR protocol. Specifically, we carried out two 
stages of PCR cycles following initial DNA denaturation. Stage one involved 7 cycles of 
gradient temperature decrease covering a range including melting temperatures (Tm) of both 
the forward and reverse primer. Stage two entailed 30 cycles at a stable annealing 
temperature, identical to that of the last cycle in stage one. After stages one and two, a final 
extension phase was allowed to continue for 10 minutes, followed by a rapid thermal ramp to 
4°C, which was held until purification occurs. The resultant PCR products were subjected to 
analysis using 1.5% agarose gel electrophoresis and then examined under ultraviolet lighting. 
Clear bands occurring at the appropriate size range were interpreted as confirming positive 
amplification. ExoSAP-IT
®
 (USB Affymetrix, Santa Clara, CA) was used for clean-up of the 
PCR products, which were subsequently sequenced overnight using a 48-capillary 3730xl 
DNA Analyzer (Applied Biosystems). The resulting sequences were analyzed using Seqscape 
software version 2.7 (Life Technologies, Carlsbad, CA, USA) with reference sequence 
NM_000314.4. Table 1 from paper II presents the primer pairs for each amplicon (forward 
and reverse), including their corresponding annealing temperatures, GC percentage content 
and size of PCR product. 
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3.3  PAPER  III 
3.3.1 Study design 
Our group undertook a study of all Swedish women with known LS nationwide. To identify 
patients for recruitment we contacted the regional departments of clinical genetics in Lund, 
Stockholm, Linkoping, Uppsala and Gothenburg, thereby covering all of Sweden except the 
extreme north. 
After searching the registries to identify women with Lynch syndrome, we contacted 260 
candidates. In all, 170 agreed to participate, while 160 of them had clinical data sufficient for 
inclusion in the study. 
We reviewed the medical records of study participants to collect information regarding 
history of gynecological surveillance of LS patients, biopsy results (if any), and any genetic 
records. Additional information was obtained concerning the details of  surveillance, with 
special focus on endometrial biopsy (EB), transvaginal ultrasound (TVUS), CA-125 testing, 
hysteroscopy, number of visits, prophylactic surgeries with age at time of procedure, current 
age, age at LS diagnosis and screening/surveillance location, where relevant 
. 
3.4 Statistical analysis 
Population data for paper I were obtained from official Swedish statistics for two separate 
years (1970 and 2010) to compensate for any differences in the incidence of cancer over time. 
Regarding different cancers among relatives of index patients, the corresponding proportions 
and confidence intervals (CIs) were calculated for each site. We compared the CIs obtained 
concerning the proportions of cancers at each site with the proportions of various cancers in 
the general population in 1970 and 2010. Any CI interval that failed to match the proportion 
from 1970 and 2010 revealed a difference for that year. Only when a significant difference in 
the proportion of malignancies was demonstrated compared with the population at large was 
under-representation or overrepresentation considered to be present. 
For categorical data we used the Pearson’s chi-square test, while any statistically significant 
differences in unpaired groups was evaluated using the Wilcoxon rank sum test. Statistical 
analysis was carried out using R software (www.r-project.org, R Core team, 2012). 
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For paper III we used the Statistica
®
 software (Statsoft.se) package to analyze data. 
Differences in groups were calculated using the Pearson’s chi-square test and Fisher’s exact 
test, Kaplan-Meier estimator, while testing of multiple groups was carried out using the 
Kruskal-Wallis test. P values <0.05 was considered significant. 
 
3.5 Ethical considerations 
The Regional Ethical Review Board at Karolinska Institutet, Stockholm, Sweden, approved 
the studies in this paper (papers I and II: 2010/1536-31/2, paper III: 2012/885-31/1). Written 
informed consent was provided by all participants. For the purpose of verifying histology 
results concerning diagnosis of cancers in relatives of female participants for papers I and II, 
written informed consent was obtained directly from relatives or their nearest surviving 
relative. The biobank number for the project is Bbk443. 
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4 RESULTS 
4.1 PAPER I 
We followed index patients for a median period of 24 months. Table 4 presents details 
regarding the characteristics of the patients. 
Median age at time of diagnosis for index patients was 67 years (range 34-95 years). 
Endometrioid carcinoma was found by histological examination in 82% of index patients, 
with most tumors (86%) confined to the uterus (FIGO stage 1) (Table 1). At follow-up 
rechecks, 17 index patients (3.5%) presented with recurrent disease (median age 70.5 years); 
12% were originally diagnosed with sarcomas, 6% with clear cell carcinoma, and 7% with 
endometrioid carcinoma. Among index patients with recurrent disease, 12% were originally 
diagnosed with stage 3 or 4 disease (compared with 7% of the cohort as a whole), while 47% 
demonstrated low-grade differentiation (compared with 22% in the cohort as a whole). 
 
4.1.1 Proportion of different cancer types among relatives 
A total of 1316 cancers were reported among relatives of index patients. Uterine cancer (6%) 
showed up in a higher proportion than in the cancer population at large in both 1970 (4%) and 
2010 (3%) (Table 3 in paper I). When we examined first-degree relatives alone, and first- and 
second-degree relatives combined, we found a similar overrepresentation. While cancers such 
as stomach/unspecified abdomen, larynx and bone were also overrepresented among 
relatives, other cancers including breast (16%), colon (8%), rectal (3%) and ovarian (2%) 
were not. 
In fact, certain cancers were underrepresented, including cancers of the rectum, pancreas, 
urinary tract, non-Hodgkin lymphoma, lip/tongue/mouth, endocrine glands (excluding 
thyroid), pharynx, small intestine, peritoneum, nose, mediastinum, eye and myelofibrosis 
(table 3 in paper I). 
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Table 4: Characteristics: 481 index patients 
Characteristics Number/Total (%)* Median Range 
[Min, Max] 
Age at diagnosis, years   67 [34, 95] 
Body mass index at diagnosis   26.3 [17.6, 55.1] 
Hormone replacement therapy 239/452 (52.9)   
Parity   2 [0, 8] 
Diabetes mellitus 51/462 (11)   
Lipid-lowering drugs 102/455 (22.4)   
Histology     
Endometrioid 394/481 (81.9)   
Serous or mixed 56/481 (11.6)   
Clear cell 9/481 (1.9)   
Sarcoma 20/481 (4.2)   
Hyperplasia with atypia 2/481 (0.4)   
FIGO stage     
1A 316/480 (65.8)   
1B 95/480 (19.8)   
2 34/480 (7.1)   
3A 16/480 (3.3)   
3B 7/480 (1.5)   
3C 2/480 (0.4)   
4 3/480 (0.6)   
4B 7/480 (1.5)   
Grade     
1 193/480 (40.2)   
2 181/480 (37.7)   
3 106/480 (22.1)   
Depth of myometrial invasion     
None 64/481 (13.3)   
<50% 282/481 (58.6)   
≥50%  128/481 (26.6)   
Spread through serosa 7/481 (1.5)   
Relapse 17/481 (3.5)   
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4.1.2 Hereditary cancer syndromes 
After assessing the pedigrees nine of 481 index patients (2%) met the Amsterdam II criteria 
for diagnosis of LS. Endometrioid cancer was present in all nine patients and seven mutations 
were identified: three in MLH1 (c.546-2A>G; c.790+1G>C and deletion of exon 1-3) and 
four in MSH2 (c.1147C>T; c.1786_1788del; deletion of exon 7-10 and deletion from exon 3 
of the EPCAM gene to exon 6 of MSH2). While one patient was previously known to belong 
to an LS family, six new LS families were now subsequently diagnosed. Interestingly, two 
LS index patients had no known colorectal cancer in their family history (figure 6). 
Since none of the index patients met the National Comprehensive Cancer Network guidelines 
for Cowden syndrome, they were not screened for PTEN gene mutations. 
Six of the nine patients who met the HBOC criteria were screened for BRCA1 and BRCA2 
mutations, but none were found. The remaining three had refused further genetic counseling 
and/or investigation. 
. 
 
 
 
Figure 6: Pedigrees of two families diagnosed with LS. MSH 2, del exon 7–10 and MSH2, 
c1147C > T mutations were diagnosed during the study. Notably, none of the families had 
any history of known colorectal cancer. Adapted from Tzortzatos et al. Hereditary Cancer 
in Clinical Practice 2014 12:14, under the Creative Commons Attribution (CC-BY) license. 
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4.1.3 Family history of cancer 
Table 1 in paper I shows the family history of cancer for index patients, among index whom 
17% had a family history of breast cancer, 12% colorectal cancer and 6% ovarian cancer. 
We compared the families of the 64 index patients who had at least one relative with uterine 
cancer (13%) with the families of the 417 index patients who had no relatives with uterine 
cancer (Table 4 in paper I). We found a significant difference in the number of family 
members diagnosed with cancer (p<0.001) between the two groups, but no differences were 
found in histology, age at diagnosis, stage, relapse, ploidy and presence of multiple cancers. 
Lynch syndrome could be identified in four of the thirty families that had relatives with 
uterine cancer and in two families in which uterine cancer occurred before age 50 in at least 
one relative or in the index case (12 of 64 families). 
We found six families, three in which the index patient was diagnosed before age 50, with at 
least two cases of uterine cancer but with no other cancers, possibly indicating site-specific 
heredity for uterine cancer. 
 
4.1.4 Multiple cancers in index patients 
We also searched for the presence of other cancers in index patients and found that 16% had 
at least one additional cancer (table 5, paper I). Of these, breast cancer occurred together with 
uterine cancer in 45% of cases. Uterine cancers predominantly demonstrated endometrioid 
histopathology (80%), although other types were also found, including 6% each of serous 
carcinoma, clear cell carcinoma and sarcoma, as well as 3% mixed type. 
In addition, colorectal cancer was present in 19% of index patients and within this group, 
86% of uterine cancers were endometrioid type, while 7% were serous carcinoma and 7% 
clear cell carcinoma. 
In four index cases (5%), the diagnosis of ovarian cancer accompanied that of uterine cancer, 
with histopathology demonstrating three endometrioid carcinomas and one serous carcinoma. 
As shown by table 5, paper I, nine index patients were diagnosed with at least three cancers. 
Four of the 75 patients with multiple cancers were identified as belonging to LS families. 
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4.2  PAPER II 
No patients met the NCCN diagnostic criteria for Cowden syndrome, but 54 patients were 
identified as having CS-like families. No germline mutations or polymorphisms were found 
to involve any of the nine exons of the PTEN gene. 
4.3  PAPER III 
Prior to being diagnosed with LS, 43 patients had undergone hysterectomy with or without 
bilateral salpingo-oophorectomy; these women made up the non-screened group as their prior 
surgery precluded meaningful screening/surveillance. This left 117 women eligible for 
screening (screened group), of whom 26 women aged 20-30 had not yet reached the age to 
participate in the screening process, while three other women had not been informed about 
screening and two more chose not to attend surveillance, leaving a total of 86 patients who 
did attend screening. 
4.3.1 Mutation spectrum and cancer incidence 
Mutations found among the 160 LS patients were as follows: 79 with MLH1, 51 with MSH2, 
25 with MSH6, and 5 with PMS2 mutations. The corresponding figures for the preceding 
mutational spectrum among the 117 eligible patients were as follows: 62, 31, 19, and 5, 
respectively. The corresponding figures for the 86 patients in the screened group were 40, 26, 
17, and 3. Finally, the figures for the non-screened group were 17 with MLH1, 20 with 
MSH2, 6 with MSH6, and none with PMS2 mutations. 
Across the board, EC/complex atypical hyperplasia (CAH) developed in 20% of MLH1 
carriers, 11.5% of MSH2, 11.7% of MSH6, and 0% of PMS2 of the 86 patients. Moreover, 
OC afflicted 4.38% of MSH2 carriers. 
4.3.2 Cancer incidence 
Among the 86 patients in the screened group the total incidence of gynecological cancer was 
15% (13% EC/CAH, 2% OC). 
Meanwhile, among women in the non-screened group 35 were diagnosed with EC (81.4%), 
three with OC (7 %) and one with colorectal cancer. When comparing mean age at time of 
cancer diagnosis there was no significant difference between the screened group, 48.5 years 
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(range 40-80 years), and the non-screened group who had undergone hysterectomy before LS 
was diagnosed, 52 years (range 35-68 years). 
Prophylactic surgery in the group of screened women was carried out on 41 patients at a 
median age of 53 (range 40-77 years) with the following breakdown of surgical procedures: 
32 women with hysterectomy and bilateral salpingo-oophorectomy (BSO), seven with 
hysterectomy alone and two with BSO alone. Postoperative histopathological findings 
showed EC/CAH in four patients (9.8%) at a median age of 47.5 (range 42-58 years). 
The screened group included 45 women, median age 41 (range 24-84 years), who presented 
for annual gynecological screening. Eleven (24%) of these women subsequently developed 
gynecological cancer; nine were diagnosed with EC/CAH (20%) and two with OC (4%). 
Gynecological screening detected five cases of EC/CAH (median age 48, range 42-80 years), 
while symptoms of intermittent bleeding led to the discovery of four more cases (median age 
46.5, range 40-59 years) (table 1). The two cases of ovarian cancer, involving women aged 
38 and 45, were found by TVUS during recheck visits (table 1, paper III). 
 
4.3.3 Diagnostic screening modalities 
Transvaginal ultrasound examination (TVUS) 
All women who presented for gynecological screening underwent TUVS. Endometrial 
thickening, as noted by TVUS, was found in two of four patients with EC and intermittent 
bleeding symptoms. TVUS also revealed the two cases of OC. 
Endometrial biopsy (EB) 
In all, 28 women (33%) underwent endometrial biopsy as part of their gynecological 
screening. A significant proportion of the women who presented for screening were found to 
have cancer, as diagnosed through EB. 
EB contributed to the diagnosis of all cancers and premalignant lesions among both 
symptomatic and asymptomatic patients who presented for screening. However, one patient 
who previously had a negative EB was later found to have EC/CAH following prophylactic 
hysterectomy. 
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Tumor marker cancer antigen (CA) 125 
The Ca-125 marker for ovarian cancer was assessed in 27 patients (29%). Of the two patients 
who were found to develop ovarian cancer, a borderline elevation of Ca-125 (36kU/L 
compared with the reference limit of 35kU/L) was found in the single patient who was 
screened. 
Hysteroscopy 
Hysteroscopy, in three cases motivated by the finding of a suspicious polyp on TVUS, was 
carried out on four patients who presented for screening. In two of these three cases, a benign 
polyp was confirmed by hysteroscopy, while the third case showed normal endometrium. 
Intermittent bleeding was the motivation for hysteroscopy in the fourth patient, for whom 
findings were also normal. 
Prophylactic surgery vs. no surgery 
When comparing the group of women who underwent prophylactic surgery with those 
who had no surgery, the incidence of cancer/premalignant lesions in the latter group was 24% 
(11 cases=9 EC/CAH, 2 OC, 20% EC/CAH, 4% OC), while the incidence in the former 
group was 9.75% (2 cases each of EC and CAH based on postoperative histopathological 
findings), which represents a significantly lower incidence of cancer in the operated group 
(p=0.036). 
 Screening setting 
We wanted to find out whether incidence of cancer differed based on screening methodology 
or screening setting (private, county, university). 
We found no difference in incidence of cancer based on screening setting. Patients who 
attended screening in the private setting and those who underwent prophylactic surgery 
tended to have a higher age and a broader age interval, although the difference in comparison 
with the other two settings was not significant. Moreover, compared with university and 
county clinics, the private setting was associated with more screening visits and fewer 
prophylactic procedures. CA-125-testing was done more frequently in private clinics, while 
endometrial biopsy was equally common in all settings. 
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Educational level 
The educational level of patients in the screening group was not associated with any 
differences in the number or type of recheck visits. 
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5 DISCUSSION 
5.1 PAPER I 
To determine whether cancer in the family history is a risk factor for uterine cancer we 
studied a Swedish patient population with uterine cancer and confirmed an association 
between family history and occurrence of uterine cancer. Our research showed that among 
index patients at least 13% had a family member with uterine cancer (7% with at least one 
FDR with diagnosed uterine cancer) and that families in our cohort experienced an increased 
relative proportion of uterine cancer, compared with incidence of cancer in the population at 
large for the years 1970 and 2010. 
The combination of multiple cancers present in any one individual and early age (<50years) 
at diagnosis of cancer is suspicious for hereditary cancer syndrome. We found that among 
patients in our cohort who had at least two cases of uterine cancer in the same family, 47% 
had family members diagnosed with cancer at an early age (<50 years). LS, a known 
hereditary syndrome, was identified in only 13% of that cohort. Moreover, at least one extra 
cancer was found in 17% of index patients ( Tzortzatos et al. 2014). 
As many other studies on uterine cancer have shown, we found an increased risk of this 
disease among first-degree relatives of uterine cancer patients, with even greater odds for 
developing uterine cancer among relatives of patients who were diagnosed before age 50 
(Parazzini et al., 1994) (Lucentaforte et al., 2009) (Hemminki et al., 2004) (von Wachenfeldt 
et al., 2007) (Hemminki et al., 1999) (Gruber et al., 1996) (Parslov et al., 2000). 
The risk for first-degree relatives of uterine cancer patients to develop endometrial cancer is 
increased when environmental factors, including obesity, may interact with genetic 
susceptibility (Seger et al., 2011). No difference in BMI (median 26.6) was seen in our study 
when comparing index patients with or without additional cases of uterine cancer. 
The relative proportion of laryngeal, stomach/abdominal and skeletal cancer was increased in 
our study, which we suggest may be due to misclassification regarding metastasis (skeletal 
cancer), or possible problems with recall bias concerning information and classification of 
cases (particularly various abdominal cancers). To date uterine cancer has not been shown to 
have an association with laryngeal cancer. 
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An overrepresentation of endometrial cancer among non-BRCA1/2 breast cancer families was 
demonstrated in a comparison with the cancer population at large, which suggests a new 
breast cancer syndrome (von Wachenfeldt et al., 2007). However, our study of endometrial 
cancer patients did not find that breast cancer was overrepresented. Nevertheless, there may 
be an association between endometrial cancer and breast cancer, as implied by the finding in 
our study that 45% of our index patients suffering from multiple primary cancers had both 
EC and BC, a higher proportion than found by Delin et al. (31%) (Delin et al., 2004) and 
Uccela et al. (10%) (Uccela et al., 2011). In addition, the risk of endometrial cancer 
regardless of family history (Kazerouni et al., 2002) and endometrial serous carcinoma in 
younger women (<55 years) (Liang et al., 2011) is elevated in patients with a history of breast 
cancer. A recent study found that among seven (5%) women with uterine serous carcinoma 
who had mutations in breast cancer genes, only two had a family history of breast cancer 
(Pennington et al., 2013).Although 6% of our index patients had both breast cancer and 
serous carcinoma, we found no BRCA1/2 mutations. 
Research has found that the risk of developing endometrial carcinoma  increases with 
tamoxifen use (RR 2.2-4), especially among postmenopausal women (Fisher et al, 1998) 
(Braithwaite et al., 2003). Our study identified 12 women with a history of tamoxifen 
treatment for breast cancer who subsequently developed uterine cancer. Although there is a 
higher cumulative incidence of endometrial cancer after five years of tamoxifen treatment, 
13/1000 compared with 5.4/1000 among women who never used tamoxifen (Braithwaite et al 
2003), we are unable to attribute cases in which uterine cancer developed in our study to 
tamoxifen. 
Ovarian cancer was not found to be overrepresented in our study. Although our study 
population was not large enough to establish an association between EC and OC, 5% of our 
index patients did have OC. A similar figure (4%) was found by Uccella et al. (Uccela et al., 
2011), while a much higher figure (29%) was reported by Delin et al. (Delin et al., 2004). 
Both an increased risk of synchronous or consecutive OC following EC (especially of the 
endometrioid type) and an increased risk of EC following primary OC were reported by 
Hemminki et al. (Hemminki et al., 2003). 
Colorectal cancer was not overrepresented in our study, either; it was found in 17% of our 
index patients who had more than one cancer. The corresponding figure reported by Uccella 
et al. was lower (3%) (Uccela et al., 2011), while Delin et al. reported a figure similar to ours 
(11%) (Delin et al., 2004). LS was identified in two of 14 index patients with metachronous 
colorectal cancer. 
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The Amsterdam II criteria were met by nine families (1.9%) in our study; of these, seven 
(1.5%) were found to have LS following verification of mutation. The MLH1 gene was 
mutated in three families and the MSH2 in the other four. Similar percentages of LS (1.8-4%) 
have been reported by other studies in unselected cases of uterine cancer (Hampel et al., 
2006) (Leenen et al., 2012) (Ollikainen et al., 2005) (Egoavil et al., 2013). However, our 
finding of 1.5% LS among our cases may represent an underestimate because of the low 
sensitivity for identifying endometrial cancer (20-30%) when using the Amsterdam II criteria 
(Hampel et al., 2006) (Leenen et al., 2012). Moreover, carriers of the MSH6 mutation are less 
likely to fulfill the Amsterdam II criteria (Sjursen et al., 2010). They are at lower risk of both 
colorectal cancer (10-22% cumulative risk by age 70) and of other LS-related cancers 
(Baglieto et al., 2010) (Bonadona et al., 2011). 
We find it interesting to postulate that the small number of families we identified with two or 
more cases of uterine cancer alone may represent site-specific uterine cancer, which is 
distinct from LS. 
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5.2 PAPER II 
Although some small studies have searched for PTEN mutations in families with CS or CS-
like phenotype, ours is the first involving CS-like families with uterine cancer. 
Marsch et al. (Marsch et al., 1998) searched for germline PTEN mutations in a study of 64 
CS-like families with a family history of breast and thyroid cancer, but not EC. One cryptic 
germline mutation c.209T>C, was found in exon 3 in one family that did not strictly fulfill 
the criteria for CS, suggesting that while the international CS diagnostic criteria remain 
robust, other genes may be involved in the CS-like phenotype. 
Rustad et al. (Rustad et al., 2006) found that only the six families with CS had germline 
PTEN mutations, while the two families suspected of having CS and the eight families in 
which both breast and thyroid cancers were present did not. 
Black et al. examined PTEN for germline mutations in a series of 240 consecutive ECs (both 
type I and type II). They were only able to identify an intronic deletion, a rare polymorphism 
in one patient, but no disease-causing mutations were found. This patient had a family history 
of sarcoma, as well as breast, lung and colon cancers. The researchers concluded that PTEN 
germline mutations do not increase the risk of EC in an unselected population outside the 
context of CS (Black et al., 2005). 
Since differentiated non-medullary thyroid cancer (DTC) may affect 3-10% of individuals 
with germline PTEN mutations, Nagy et al. studied the frequency of these mutations in an 
unselected population of 259 cases of DTC, 17 of which fulfilled CS criteria. The authors 
found a very low mutation rate (0.8%), but were able to identify two deleterious mutations in 
two individuals who did meet CS criteria. They suggested combining germline PTEN 
mutational screening with histology and clinical evaluation of thyroid cancer patients (Nagy 
et al., 2011). 
Laugé et al. studied a series of 20 women with breast cancer who also had a personal history 
and/or family history of breast/brain tumors. They excluded patients with a personal or family 
history of Cowden disease as well as patients with a family history of breast cancer in which 
germline BRCA1 and p53 mutations were present. They performed point mutation analysis of 
the PTEN gene and found two previously described polymorphisms (insertion of a T in intron 
4, IVS4-29insT, and a T to G transition in intron 8, IVS8+32T/G), but no disease-associated 
mutations (Laugé et al., 1999). 
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Lynch et al. selected a series of 25 families to sequence for germline PTEN mutations in 
order to investigate whether PTEN mutations predispose to breast cancer. 
Of these families, three had CS and five had CS plus breast cancer, while four had breast and 
thyroid cancer without a definite diagnosis of CS. The remaining 13 families were at high 
risk of breast, ovarian and/or prostate cancer, with wild-type BRCA1 and BRCA2 sequences. 
Mutational analysis and DNA sequencing of the PTEN gene identified seven (five nonsense 
and two missense) mutations in 6 CS families and one CS-like family. Consequently, all 
seven of these mutations were identified in patients from CS and CS-suspected families (by 
clinical characteristics) and none were found among the remaining 13 families referred to 
above. (Lynch ED et al.1997). 
A recently published study (Castéra et al., 2014) of a large series of 708 consecutive patients 
who fulfilled HBOC criteria did not identify any germline PTEN mutations through next-
generation sequencing. Kurian et al. carried out multiple gene-sequencing analysis in 198 
women suspected of having HBOC. PTEN was one of the tested genes and no germline 
mutations were found (Kurian et al., 2014). Neither study showed any association between 
germline PTEN mutation and HBOC. 
One study carried out germline mutation analysis of the succinate dehydrogenase (SDH) gene 
on 375 CS and CS-like individuals in whom PTEN mutations were not found. CS-like 
individuals were defined as those who fell one or two criteria short of meeting all existing CS 
guidelines. Ten germline mutations/variants in the SDHB and SDHD genes were identified in 
these patients that were not found in healthy controls. SDHx gene mutations affect 
mitochondrial function related to the Krebs cycle and may be associated with activation of 
pathways similar to those that PTEN mutations affect. Significantly higher frequencies of 
breast cancer, as well as thyroid and renal cell carcinomas were found among carriers of the 
SDHx mutation compared with carriers of germline PTEN mutations. They postulate that this 
gene may be an indicator of susceptibility among CS and CS-like individuals when germline 
PTEN mutations are not present (Ni et al., 2008). 
Bennet et al. showed hypermethylation of KILLIN in 30% of all cases among 123 CS and CS-
like individuals who tested negative for germline PTEN mutations. Disruption of p53-
activation was also seen and these changes were associated with increased risk of breast and 
renal cancer among PTEN mutation-positive patients. CS-like individuals shared some 
features of CS without meeting diagnostic criteria (Bennet et al., 2010). 
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Another study of 103 patients with primary breast cancer and 25 patients with familial breast 
cancer identified no germline PTEN mutations, leading the authors to conclude that PTEN 
gene alterations are rare in relation to breast cancers. (Freihoff et al., 1999). 
A recent study examined 91 CS and CS-like individuals, who did not exhibit any 
PTEN/SDHx/KILLIN mutations, for the presence of mutations in other genes along the 
AKT/PIK3CA/mTOR pathway. A total of 8.8% were found to have germline PIK3CA 
mutations and 2.2% AKT1 mutations. The authors showed that this resulted in increased 
cellular PIP3 and phosphorylation of AKT1, suggesting that PIK3CA and AKT1 are CS 
susceptibility genes (Orloff et al., 2013). 
Other studies have shown that about 10% of PTEN mutation-negative CS patients have 
nucleotide variants within the full length of the promoter region that can cause either a 
decrease in PTEN protein expression or loss of function. Since 89% of these patients had 
breast cancer, the authors suggested that these mutations had very high penetrance for breast 
cancer (Zhou et al., 2003). Teresi et al. examined miscellaneous PTEN promoter nucleotide 
variations of unknown significance in CS patients and found that some of these variations led 
to decreased PTEN expression through dysfunctional translation, rather than by affecting 
transcription (Teresi et al., 2007). Liu et al. identified a novel PTEN mutation located in 1.312 
(G<T) within the promoter region in a patient whose pedigree suggested CS. Since this is the 
p53-binding sequence region, it may affect p53-induced PTEN expression. No mutations 
were identified in the nine exons of PTEN. However, the authors were unable to determine 
whether oncogenesis in this patient could be attributed to a KILLIN mutation or PTEN 
hypermethylation (Liu et al., 2013). 
Our study has two major flaws: the small number of patients and the lack of a detailed 
phenotypic evaluation of patients to obtain information on head-circumference (associated 
with increased risk of cancer in CS patients) or on non-cancer phenotype. On the other hand, 
this project was carried out in the real clinical world on CS-like families referred for germline 
mutation screening based on their family history alone. 
To conclude, we detected no germline PTEN mutations in our cohort of CS-like patients, 
suggesting that screening for PTEN mutations in such patients has no clinical relevance 
unless patients meet strict CS diagnostic criteria. We did not search for large genomic 
deletions/duplication of one or more exons. Large deletions are common in somatic 
alterations, but are not found as constitutional PTEN mutations (Zhou et al., 2003). We did 
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not check for mutations in the promoter region because germline mutations in that area are 
uncommon (Zhou et al., 2003). 
 
5.3 PAPER III 
We showed that screening Lynch syndrome patients for gynecological malignancy reduces 
the incidence of cancer. Endometrial biopsy is an effective method for diagnosing 
endometrial cancer and precancerous lesions. Prophylactic hysterectomy with or without 
bilateral salpingo-oophorectomy significantly reduces the incidence of cancer. 
In the non-screened group we found an 81.4% incidence of EC, compared with 13% in the 
screened group. Most cases of EC are detected at an early stage and patients are cured by 
surgery. Therefore it remains unclear whether EC screening reduces morbidity and mortality. 
One study (de Jong et al., 2006) showed a decrease in mortality among patients who attended 
an annual screening program that included TVUS and CA-125, but further studies are needed 
to evaluate the efficacy of screening programs regarding morbidity and mortality. 
We found that the use of EB in screening settings was of benefit to LS women, since more 
cases of EC were found when EB was used. 
The findings in our study are consistent with those of Renkonen-Sinisalo et al. (Renkonen-
Sinisalo et al., 2007). These authors demonstrated clear differences in screening accuracy 
when comparing the various diagnostic tools used to detect cancer. They also showed that the 
ability to detect EC at the screening visit largely depended on whether or not EB was used. 
Another important result from that study was the finding of 14 additional premalignant cases 
using EB that were missed on TVUS, thereby leading to fewer cases of cancer and ultimately 
to decreased mortality and morbidity within the screened group. 
Nowadays, since TVUS is routinely used for screening in every gynecological practice we 
were unable to compare results between TVUS and non-TVUS groups in our study. 
However, no EC was found by TVUS in any of our reported cases, which contradicts a study 
by Helder-Woolderink et al. (Helder-Woolderink et al., 2013), in which annual TVUS 
detected all premalignant cases, with no added value from EB. Meanwhile, a screening 
program study that followed 292 LS women for 13 years using only TVUS screening did not 
detect any cases of EC (Dove-Edwin et al., 2002). This was a large study and therefore 
 42 
 
clearly shows that TVUS alone is insufficient to detect EC, which is well in line with our 
results. 
The drawbacks of annual EB are the small risk of complications (infection and possible tissue 
damage, such as perforation of the uterus) and discomfort from the procedure (Elmarsy et al., 
2009). Therefore the risk is that women may choose not to attend screening, thereby lowering 
compliance (Crispens et al., 2012). They may also opt for prophylactic surgery because of the 
screening procedure (Helder-Woolderink et al., 2013). However, other authors suggest that 
both hysteroscopy and EB are well-tolerated outpatient procedures (Manchada et al., 2012) 
(Järvinen et al., 2009). A newly proposed strategy is to perform EB simultaneously with 
colonoscopy rechecks in an effort to reduce pain, discomfort and anxiety. This strategy has 
been tested at some centers and has been shown to improve screening accuracy and 
compliance (Huang et al., 2011). 
Hysterectomy with/without bilateral SOE as a method of preventing cancer is almost 100% 
effective regarding both EC and OC (Schmeler et al., 2006). Owing to the small number of 
patients in prophylactic surgery groups, it has not been possible to ascertain the reduction in 
mortality in any of these studies (Renkonen-Sinisalo et al., 2007) (Crispens et al., 2012) 
(Schmeler et al., 2006) (Boilesen et al., 2008). The disadvantages of prophylactic 
hysterectomy include general surgical complications and premature menopause associated 
with bilateral SOE (Nakamura et al., 2014) (Schmeler et al., 2006). Patients should be 
informed not only about the probable reduction in risk of cancer from prophylactic surgery, 
but also about negative effects on childbearing, as well as potential secondary surgical 
complications and complications associated with premature menopause. The literature is 
nearly unanimous in recommending total prophylactic hysterectomy with/without bilateral 
SOE once childbearing is completed (NCCN guidelines, 2013) (Vasen et al., 2013) (Järvinen 
et al., 2009) ((Schmeler et al., 2006) (Lachiewicz et al., 2014) and after all the pros and cons 
of prophylactic surgery have been discussed (Vasen et al., 2013) (Nakamura et al., 2014), or 
the procedure can be done in conjunction with colorectal cancer surgery (Nakamura et al., 
2014). Many studies underscore how important it is for gynecologists to be aware of the 
possibility that malignancy may already be present when they undertake prophylactic surgery 
(Schmeler et al., 2006) (Lachiewicz et al., 2014) (Lu et al., 2013) (Backes et al., 2011). 
There is no consensus about the age at which a patient should be included in a gynecological 
surveillance program. Since the youngest cancer patient in our material was 35 years old and 
the oldest 80 years old we suggest that gynecological surveillance should begin at least five 
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years prior to the earliest case, i.e. from 30 years of age and continue into old age. To date no 
upper age limit for surveillance has been defined (Vasen et al., 2013) (Auranen et al., 2011) 
(Ketabi et al., 2014). 
In our material, two women in the screened group developed ovarian cancer (1.7%) which is 
in consistent with other studies (Auranen et al., 2011) (Renkonen-Sinisalo et al., 2007) 
(Järvinen et al., 2009) (Boilesen et al., 2008). TVUS detected both cases without any 
diagnostic contribution from Ca-125. The cases of OC reported by Renkonen-Sinisalo et al. 
(Renkonen-Sinisalo et al., 2007) were not discovered through surveillance, but only 
diagnosed as a result of symptoms or incidentally at surgery. Similarly, no cases of OC were 
discovered through surveillance in the studies reported by Auranen et al. (Auranen et al., 
2011). Screening results for OC among LS patients are very few and usually not significant 
due to the low number of cases. Gynecologists use both TVUS and the Ca-125 tumor marker 
to screen for OC, but so far neither test has proven to be significantly effective for preventing 
mortality from OC (Gaarenström et al., 2006). The prognosis for ovarian cancer in LS 
patients may be better than in patients with sporadic ovarian cancer (Nakamura et al., 2014) 
(Backes et al., 2011) (Grindedal et al., 2010), although not all studies agree (Crijnen et al., 
2005). 
No differences were found in the number or types of screening visits in relation to 
educational level in our cohort, but we were unable to measure the impact on compliance. 
Increased compliance may correlate with higher educational levels, as suggested by Ketabi et 
al. (Ketabi et al., 2012), perhaps due to a better understanding among highly educated women 
regarding the risks of EC and OC. 
We found no significant differences in the type of screening or incidence of cancer among the 
various medical settings where surveillance was conducted. The only difference between 
county and university hospitals was that the former used Ca-125 more frequently than the 
latter. These two types of gynecological clinics were similar in all other respects, perhaps due 
to the small number of patients overall, or this result may reflect a trend among gynecologists 
to comply with national guidelines for LS patients. 
One limitation of our study is its retrospective design. Selection bias may be present. Women 
who are aware of their increased risk of cancer may be more likely to participate in the study. 
No information is available about the women who chose not to participate. However, all 
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cancer diagnoses were obtained from medical records, thereby eliminating any recall or 
ascertainment bias. 
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6 GENERAL CONCLUSIONS 
 In an unselected uterine cancer population we identified an overrepresentation of 
uterine cancer among first-degree and second-degree relatives and first cousins of 
patients. We suspect that a common genetic factor, and/or common environmental 
and lifestyle factors may account for this.  
 Our data raise suspicion of a possible hereditary uterine cancer syndrome because we 
observed an increased incidence of cancer occurring before age 50 in relatives of 
patients with uterine cancer, as well as an increased incidence of multiple cancers 
among index patients. 
 We also determined that the prevalence of Lynch syndrome is about 2% and of the 
seven families diagnosed with LS in our study, only one was previously known. The 
family history of all these families should have alerted physicians to suspect LS. 
 All gynecologists should be aware that the prevalence of LS among endometrial 
cancer patients is at least 2% and a careful family history should be obtained from 
these patients. In addition, relatives of uterine cancer patients are at increased risk of 
uterine cancer. Gynecologists should not hesitate to refer suspected cases for genetic 
counseling and investigation. Both gynecologists and clinical geneticists should 
work toward improving strategies for identification, follow-up and surveillance of 
individuals at increased risk for uterine cancer. 
 We showed that germline PTEN mutations are rare in CS-like families with 
endometrial cancer. 
 Screening for PTEN mutations among endometrial cancer patients with CS-like 
phenotype is expensive and has been routine procedure at oncogenetic clinics. We 
suggest that testing should be aimed only at patients who meet strict CS criteria. 
 Gynecologists should also be aware of CS criteria and should apply them in daily 
clinical practice in order to identify and refer women with possible CS who present 
with endometrial cancer. 
 Gynecologists should inform female LS patients about the advantages and 
disadvantages of prophylactic surgery and the importance of gynecological 
surveillance, as well as about early symptoms of gynecological cancer. Emphasis 
should be placed on the risk of cancer and average age at onset. 
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 We suggest that screening should begin at age 30-35 and include TVUS and probably 
EB to improve diagnostic accuracy. Prophylactic surgery should be recommended 
after childbearing at a suitable age. 
 All gynecologists should be regularly updated about current national 
recommendations for screening, treatment and follow-up of female LS patients. 
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7 FUTURE PERSPECTIVES 
 
 Our center may also conduct a large LS prevalence study in the future using both IHC 
and MSI to examine all endometrial cancer tumors. Such a study may also include 
tumors from other cancer centers in Sweden. Possibly it could reveal that the 
prevalence of LS in consecutive endometrial cancer patients may be higher than 
expected, as we postulated in our first study. A future study could also assess whether 
screening for LS by IHC or clinical criteria among endometrial cancer patients is cost-
effective. 
 A future study might appropriately examine family history of cancer and the 
prevalence of hereditary cancer syndromes such as LS and HBOC in an unselected 
group of ovarian cancer patients using the same approach and methodology as 
described in paper I. 
 In the future, larger population-based studies covering a longer period and with 
more patients enrolled could be used to evaluate the possible impact of 
environmental and lifestyle factors (other than obesity) on the development of 
endometrial cancer. 
 One focus for current and future studies is the identification of possible low-risk 
genes that may explain familial predisposition for uterine cancer. Genome-wide 
association studies are underway looking for possible disease-causing loci/genes that 
may play a role in endometrial carcinogenesis. Such studies could shed sufficient light 
on the biological pathways leading to EC to improve future screening for at-risk 
patients and enable formulation of targeted treatments. Our research group 
RENDOCAS is participating in such research through collaboration with other 
international groups. 
 Future studies involving greater numbers of CS and CS-like patients may focus on the 
analysis of other genes, such as SDHx, PIK3CA, AKT1 and KILLIN, as well as the 
promoter region of the PTEN gene, when no germline PTEN mutations are present in 
order to investigate the prevalence of other mutations in such patients. 
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 Large population-based studies covering a long time span and having access to cancer 
registries may help evaluate the effect of surveillance and prophylactic surgery, 
especially regarding morbidity and mortality over time for women with LS. 
 Further studies are needed to assess anxiety in female patients who have been 
informed that they have LS, especially since attending a surveillance program may 
cause significant distress. Other studies might address various psychological issues, 
including anxiety and distress due to awareness of the increased lifetime risk for 
developing cancer among LS patients. Furthermore, it would be important to ascertain 
whether LS affects the decision to have children and whether women with LS would 
plan to complete childbearing earlier than other women in order to have prophylactic 
surgery.  
 Future studies should also address other issues such as clinical application of tests for 
LS and Cowden syndrome in a gynecological and oncogenetic setting, as well as cost-
effectiveness and usefulness to gynecologists and/or clinical geneticists. 
 Long-term follow-up studies could also determine whether to offer preimplantation 
genetic diagnostics (PGD) and/or prenatal testing to female LS patients and determine 
what proportion of patients would avail themselves of this option and the outcomes. It 
would also be valuable to determine how much anxiety and concern female carriers 
experience regarding the well-being of their offspring, especially if neither PGD nor 
prenatal screening have been conducted. 
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“Ithaka 
 
As you set out for Ithaka 
hope the voyage is a long one, 
full of adventure, full of discovery. 
Laistrygonians and Cyclops, 
angry Poseidon—don’t be afraid of them: 
you’ll never find things like that on your 
way 
as long as you keep your thoughts raised 
high, 
as long as a rare excitement 
stirs your spirit and your body. 
Laistrygonians and Cyclops, 
wild Poseidon—you won’t encounter them 
unless you bring them along inside your 
soul, 
unless your soul sets them up in front of 
you. 
 
Hope the voyage is a long one. 
May there be many a summer morning 
when, 
with what pleasure, what joy, 
you come into harbors seen for the first 
time; 
may you stop at Phoenician trading stations 
to buy fine things, 
mother of pearl and coral, amber and 
ebony, 
sensual perfume of every kind— 
as many sensual perfumes as you can; 
and may you visit many Egyptian cities 
to gather stores of knowledge from their 
scholars. 
 
Keep Ithaka always in your mind. 
Arriving there is what you are destined for. 
But do not hurry the journey at all. 
Better if it lasts for years, 
so you are old by the time you reach the 
Ιθάκη 
“Σα βγεις στον πηγαιμό για την Ιθάκη, 
να εύχεσαι νάναι μακρύς ο δρόμος, 
γεμάτος περιπέτειες, γεμάτος γνώσεις. 
Τους Λαιστρυγόνας και τους Κύκλωπας, 
τον θυμωμένο Ποσειδώνα μη φοβάσαι, 
τέτοια στον δρόμο σου ποτέ σου δεν θα 
βρεις, 
αν μέν’ η σκέψις σου υψηλή, αν εκλεκτή 
συγκίνησις το πνεύμα και το σώμα σου 
αγγίζει. 
Τους Λαιστρυγόνας και τους Κύκλωπας, 
τον άγριο Ποσειδώνα δεν θα συναντήσεις, 
αν δεν τους κουβανείς μες στην ψυχή σου, 
αν η ψυχή σου δεν τους στήνει εμπρός 
σου. 
 
 
Να εύχεσαι νάναι μακρύς ο δρόμος. 
Πολλά τα καλοκαιρινά πρωιά να είναι 
που με τι ευχαρίστησι, με τι χαρά 
θα μπαίνεις σε λιμένας πρωτοειδωμένους· 
να σταματήσεις σ’ εμπορεία Φοινικικά, 
και τες καλές πραγμάτειες ν’ αποκτήσεις, 
σεντέφια και κοράλλια, κεχριμπάρια κ’ 
έβενους, 
και ηδονικά μυρωδικά κάθε λογής, 
όσο μπορείς πιο άφθονα ηδονικά 
μυρωδικά· 
σε πόλεις Aιγυπτιακές πολλές να πας, 
να μάθεις και να μάθεις απ’ τους 
σπουδασμένους. 
 
 
Πάντα στον νου σου νάχεις την Ιθάκη. 
Το φθάσιμον εκεί είν’ ο προορισμός σου. 
Aλλά μη βιάζεις το ταξείδι διόλου. 
Καλλίτερα χρόνια πολλά να διαρκέσει· 
και γέρος πια ν’ αράξεις στο νησί, 
 66 
 
island, 
wealthy with all you have gained on the 
way, 
not expecting Ithaka to make you rich. 
 
Ithaka gave you the marvelous journey. 
Without her you would not have set out. 
She has nothing left to give you now. 
 
And if you find her poor, Ithaka won’t 
have fooled you. 
Wise as you will have become, so full of 
experience, 
you will have understood by then what 
these Ithakas mean.”  
― C.P. Cavafy, Collected Poems,1911 
πλούσιος με όσα κέρδισες στον δρόμο, 
μη προσδοκώντας πλούτη να σε δώσει η 
Ιθάκη. 
 
Η Ιθάκη σ’ έδωσε τ’ ωραίο ταξείδι. 
Χωρίς αυτήν δεν θάβγαινες στον δρόμο. 
Άλλα δεν έχει να σε δώσει πια. 
 
Κι αν πτωχική την βρεις, η Ιθάκη δεν σε 
γέλασε. 
Έτσι σοφός που έγινες, με τόση πείρα, 
ήδη θα το κατάλαβες η Ιθάκες τι 
σημαίνουν.”  
― C.P. Cavafy,1911 
 
 
 
